Convergent Therapeutics, Inc.
Sunny Shah, M.D. is a seasoned professional in the biotechnology sector, currently serving as a Science Committee Observer at Cardurion Pharmaceuticals since August 2024 and as Director of Biotechnology at The Invus Group since September 2020. With extensive experience in analyzing public and private biomedical companies, Sunny also serves as a Board Observer for Convergent Therapeutics, Inc. and a Stealth Biotech Company while contributing to Stanford University's Joint Research Committee for the Stanford Innovative Medicines Accelerator. Previous roles include Assistant Professor of Clinical Medicine and Director of Noninvasive Imaging at Weill Cornell Medicine from 2014 to 2020, and completing fellowships in Cardiovascular Disease and internal medicine at NYU Langone Health. Sunny holds a Doctor of Medicine degree from NYU Grossman School of Medicine and a Bachelor of Arts in Biology and Pre-Business Studies from New York University.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.